glp-1 drugs pharmaceutical companies partnerships 2025 Market Overview: GLP-1 Agonists and the Obesity Market Alarming rise in weight loss

The first comprises the exendin-4 derivatives (exenatide and lixisenatide), whose structure is based on the peptide sequence of exendin-4, which was isolated from the saliva of the Gila monster lizard (Nauck et al, 2021)

Similarly, for dual/triple agonists, regulatory agencies will demand evidence of incremental benefit vs risk over existing agents

Through a diuretic mechanism and other effects on the kidneys, GLP-1 can lower blood pressure

Aib 13 GLP-1, GIP, GCG (glucagon), and GLP-2 share high homology so that it ought to be considered that GCGR and GLP-2R should sidestep the activation of the designed GLP-1/GIP dual agonist